Astrazeneca Pharma India Ltd vs Fredun Pharmaceuticals Ltd Stock Comparison
Astrazeneca Pharma India Ltd vs Fredun Pharmaceuticals Ltd Stock Comparison
Last Updated on: May 06, 2026
Key Highlights
The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8369 as of 06 May 15:30
. The P/E Ratio of Astrazeneca Pharma India Ltd is 0 as of March 2025
.The P/E Ratio of Fredun Pharmaceuticals Ltd is 16 as of March 2025
. The Market Cap of Astrazeneca Pharma India Ltd is ₹ 0 crore as of March 2025
.The Market Cap of Fredun Pharmaceuticals Ltd is ₹ 315.67 crore as of March 2025
. The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Fredun Pharmaceuticals Ltd for the Dec '25 is ₹ 160.92 crore as compare to the Sep '25 revenue of ₹ 145.29 crore. This represent the growth of 10.76% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Fredun Pharmaceuticals Ltd for the Dec '25 is ₹ 26.34 crore as compare to the Sep '25 ebitda of ₹ 22.33 crore. This represent the growth of 17.96% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0%
The net profit of Fredun Pharmaceuticals Ltd changed from ₹ 13.74 crore to ₹ 10.48 crore over 5 quarters. This represents a CAGR of -19.48%
The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Fredun Pharmaceuticals Ltd changed from 13.9 % on March 2021 to 1.59 % on March 2025 . This represents a CAGR of -35.18% over 5 years .
About Astrazeneca Pharma India Ltd
AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology.
AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.
About Fredun Pharmaceuticals Ltd
Incorporated in 1987 as a private limited company, Fredun Pharmaceuticals Limited (FPL) was converted into a public limited company in Mar.'94.
The Company was promoted by Nariman Medhora and Daulat N Medhora.
The promoters initially established D N Pharma, a proprietary firm, for the manufacture and export of pharmaceutical formulations.
Since 1993, D N Pharma's operations were phased out in order to switch over the business to FPL.
The Company is well diversified in the business ranging from Formulations to Diagnostics to Consultancy.
The Company has an unique range of products, from niche formulations , anti-diabetics to the latest antiretroviral and anti - Hypertensive products.
FAQs for the comparison of Astrazeneca Pharma India Ltd and Fredun Pharmaceuticals Ltd
Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Fredun Pharmaceuticals Ltd?
Market cap of Astrazeneca Pharma India Ltd is 20,923 Cr while Market cap of Fredun Pharmaceuticals Ltd is 1,358 Cr
What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Fredun Pharmaceuticals Ltd?
The stock performance of Astrazeneca Pharma India Ltd and Fredun Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Astrazeneca Pharma India Ltd and Fredun Pharmaceuticals Ltd?
As of May 6, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8369.45. On the other hand, Fredun Pharmaceuticals Ltd stock price is INR ₹2464.55.
How do dividend payouts of Astrazeneca Pharma India Ltd and Fredun Pharmaceuticals Ltd compare?
To compare the dividend payouts of Astrazeneca Pharma India Ltd and Fredun Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.